Elanco Animal Health (NYSE:ELAN) Issues Q2 2022 Earnings Guidance

Elanco Animal Health (NYSE:ELAN – Get Rating) issued an update on its second quarter 2022 earnings guidance on Monday morning. The company provided EPS guidance of $0.22-$0.28 for the period, compared to the consensus EPS estimate of $0.34. The company issued revenue guidance of $1.16 billion-$1.20 billion, compared to the consensus revenue estimate of $1.27 billion.Elanco Animal Health also updated its FY 2022 guidance to $1.15-$1.21 EPS.

ELAN stock opened at $24.19 on Monday. The company has a debt-to-equity ratio of 0.80, a current ratio of 2.44 and a quick ratio of 1.41. The firm has a market capitalization of $11.47 billion, a P/E ratio of -32.69, a P/E/G ratio of 1.18 and a beta of 0.74. The business’s 50-day moving average is $24.84 and its two-hundred day moving average is $26.54. Elanco Animal Health has a 1 year low of $20.51 and a 1 year high of $37.49.

Elanco Animal Health (NYSE:ELAN – Get Rating) last issued its earnings results on Monday, May 9th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.01. The business had revenue of $1.23 billion for the quarter, compared to analyst estimates of $1.22 billion. Elanco Animal Health had a positive return on equity of 6.61% and a negative net margin of 7.65%. The business’s quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter last year, the company earned $0.37 EPS. On average, analysts expect that Elanco Animal Health will post 1.17 EPS for the current year.

A number of analysts recently weighed in on the company. Barclays lifted their price target on Elanco Animal Health from $30.00 to $32.00 and gave the company an equal weight rating in a research note on Monday, February 28th. Zacks Investment Research downgraded Elanco Animal Health from a hold rating to a sell rating in a research report on Tuesday, May 10th. Morgan Stanley reduced their target price on Elanco Animal Health to $37.00 and set an overweight rating on the stock in a research report on Tuesday, May 17th. Finally, The Goldman Sachs Group reduced their target price on Elanco Animal Health from $37.00 to $32.00 and set a buy rating on the stock in a research report on Thursday, May 19th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Hold and a consensus target price of $34.60.

In other news, Director John P. Bilbrey acquired 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Wednesday, May 11th. The stock was purchased at an average price of $22.03 per share, with a total value of $220,300.00. Following the completion of the transaction, the director now owns 34,222 shares in the company, valued at $753,910.66. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 6.40% of the company’s stock.

Several institutional investors have recently modified their holdings of the business. Guggenheim Capital LLC increased its position in shares of Elanco Animal Health by 71.6% in the 4th quarter. Guggenheim Capital LLC now owns 18,787 shares of the company’s stock valued at $533,000 after buying an additional 7,839 shares in the last quarter. CIBC World Markets Inc. bought a new position in Elanco Animal Health in the fourth quarter valued at approximately $376,000. MML Investors Services LLC boosted its position in Elanco Animal Health by 6.7% in the fourth quarter. MML Investors Services LLC now owns 15,449 shares of the company’s stock valued at $438,000 after buying an additional 974 shares in the last quarter. Mackenzie Financial Corp lifted its holdings in shares of Elanco Animal Health by 18.8% during the fourth quarter. Mackenzie Financial Corp now owns 39,328 shares of the company’s stock worth $1,116,000 after purchasing an additional 6,225 shares during the period. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Elanco Animal Health in the fourth quarter valued at $1,167,000.

About Elanco Animal Health (Get Rating)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Elanco Animal Health right now?

Before you consider Elanco Animal Health, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Elanco Animal Health wasn’t on the list.

While Elanco Animal Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here